This is Part 1 of High-Risk HR-Positive, HER2-Negative Early-Stage Breast Cancer: Bridging Evidence, Risk Identification, and Real-World Practice, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.

 

In this video, Sara Tolaney, MD, MPH, FASCO, Erica Mayer, MD, MPH, FASCO, and Elahe Salehi, DNP, ANP-BC, discuss identifying and managing high-risk hormone receptor–positive, HER2-negative early breast cancer. They review the case of a 62-year-old postmenopausal woman with a 4.5-cm, grade 1 invasive lobular carcinoma and two positive lymph nodes. Despite high anatomic risk, her biology was favorable with a Ki-67 of 5% and an Oncotype Recurrence Score of 8.

 

The faculty highlight how to interpret discordant risk factors, the role of extended endocrine therapy as the bedrock of treatment, considerations around adding a CDK4/6 inhibitor in high-risk postmenopausal patients, and strategies for sequencing therapy with radiation to manage potential side effects.